<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830399</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01810-49</org_study_id>
    <nct_id>NCT02830399</nct_id>
  </id_info>
  <brief_title>Clinical Trial on Efficacy of rTMS to Improve ECT in Treatment-Resistant Depression</brief_title>
  <acronym>STIMAGNECT</acronym>
  <official_title>Clinical Trial on Efficacy of Repeated Transcranial Magnetic Stimulation (rTMS) to Improve Electroconvulsive Therapy (ECT) in Treatment-Resistant Depression (TRD): STIMAGNECT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier du Rouvray</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Henri Laborit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier du Rouvray</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It's a prospective, multicentric, randomized, controlled study concerning 56 patients with&#xD;
      treatment-resistant depression (TRD). The main objective of this study was to evaluate the&#xD;
      efficacy of priming repeated Transcranial Magnetic Stimulation (rTMS) sessions before&#xD;
      Electroconvulsive therapy (ECT) for treatment of TRD patients. The primary outcome will be&#xD;
      the depressive symptoms intensity measured with the Hamilton Rating Scale For Depression&#xD;
      (HAMD-21 items) after 5 ECT. The secondary outcome is to evaluate the safety and most&#xD;
      particularly the cognitive effects of this association.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Included patients are adults, aged between 18 and 70 years, with major depression (Hamilton&#xD;
      Rating scale for Depression, HAMD ≥ 15). Patients don't have any experience concerning&#xD;
      repeated Transcranial Magnetic Stimulation (rTMS).&#xD;
&#xD;
      Patients with treatment-resistant depression (TRD) were assigned to two treatment groups in&#xD;
      addition to their current pharmacotherapy regimen : one group received 5 active-rTMS before&#xD;
      Electroconvulsive therapy (ECT) and the other one received sham-rTMS before ECT. The&#xD;
      depressive symptoms and the cognitive functions are evaluated before rTMS, after 5 rTMS and&#xD;
      after 5 ECT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2016</start_date>
  <completion_date type="Actual">July 12, 2019</completion_date>
  <primary_completion_date type="Actual">July 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative improvement of the Hamilton Rating Scale for Depression 21-items score</measure>
    <time_frame>Relative improvement of the Hamilton Rating Scale for Depression score between the inclusion and 19 days after the inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>active rTMS-ECT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 active high frequency rTMS before 5 bilateral ECT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham rTMS-ECT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 sham rTMS before 5 bilateral ECT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>active rTMS-ECT</intervention_name>
    <description>5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT</description>
    <arm_group_label>active rTMS-ECT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham rTMS-ECT</intervention_name>
    <description>5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT</description>
    <arm_group_label>sham rTMS-ECT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Major Depressive Disorder (HAMD≥15)&#xD;
&#xD;
          -  Level of resistance ≥ 3 (Thase and Rush)&#xD;
&#xD;
          -  Participants who gave their informed, written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication of Electroconvulsive therapy (ECT), repeated Transcranial Magnetic&#xD;
             Stimulation (rTMS), Magnetic Resonance Imaging (MRI), anesthesia&#xD;
&#xD;
          -  History of epilepsy; severe neurological or systemic disorder that could significantly&#xD;
             affect cognition&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Esquirol- CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Laborit</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Rouvray</name>
      <address>
        <city>Sotteville-lès-Rouen</city>
        <zip>76300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier du Rouvray</investigator_affiliation>
    <investigator_full_name>Maud Rothärmel</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>treatment-resistant-depression</keyword>
  <keyword>rTMS</keyword>
  <keyword>ECT</keyword>
  <keyword>Augmentation strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

